Novo's oral GLP-1 analog meets primary in Phase IIIa diabetes, renal impairment study

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral semaglutide met the primary endpoint in the Phase IIIa PIONEER 5 trial to treat Type II diabetes and moderate renal impairment. Compared with placebo, the oral long-acting glucagon-like peptide-1 (GLP-1) analog reduced HbA1c from baseline to week 26, irrespective of treatment discontinuation and use of rescue medication. Oral semaglutide also met the secondary endpoint of reducing body weight from baseline to week 26 vs. placebo.

The double-blind, international trial evaluated once-daily 14 mg oral semaglutide in 324 patients inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin...